Monoclonal antibody protection from age-dependent poliomyelitis: implications regarding the pathogenesis of lactate dehydrogenase-elevating virus.
Over 90% of cyclophosphamide-treated, 6- to 7-month-old C58/M mice developed fatal paralytic disease after infection with a virulent strain of lactate dehydrogenase-elevating virus (LDV), with a mean onset of paralysis of about 16 days. Passive immunization with polyclonal antibodies or with a group of anti-LDV monoclonal antibodies (MAbs) with single-epitope specificity 1 day before or at the time of LDV infection prevented the development of paralytic disease without interfering with the replication of LDV in permissive macrophages, the primary host cells of LDV. In situ hybridization of spinal cord sections with an LDV-specific cDNA probe indicated that the MAb specifically prevented the cytocidal infection of motor neurons by LDV without blocking the infection of smaller nonneuronal cells in the spinal cord. The protective antibodies recognize at least two different epitopes on the glycoprotein of LDV, VP-3. Passive immunizations with other anti-LDV MAbs, which recognize at least three other epitopes on VP-3 of LDV, afforded no protection. In contrast to the protective effect of anti-LDV MAb injection before or at the time of LDV infection, their administration postinfection exerted relatively little protection, though it delayed the appearance of paralytic symptoms. However, repeated injections of MAbs until at least 7 days postinfection also afforded a high degree of protection. The results indicate that protective MAbs may interfere with two stages in the development of LDV-induced paralytic disease. When administered at the time of LDV infection, they prevent the initial infection of spinal cord motor neurons. After this initial event, repeated injections of MAb are required to inhibit the spread of LDV between neurons until the endogenous production of protective anti-LDV antibodies in these mice.
Harty
J T
JT
Department of Microbiology, University of Minnesota Medical School, Minneapolis 55455-0312.
Plagemann
P G
PG
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000494:pharmacology; D005260:Female; D007772:Lactate dehydrogenase-elevating virus / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity* / Q000502:physiology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009046:Motor Neurons / Q000502:physiology; D011051:Poliomyelitis / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D012367:RNA, Viral / Q000302:isolation & purification; D013116:Spinal Cord / Q000382:microbiology* / Q000473:pathology; D014779:Virus Replication / Q000187:drug effects
D000911:Antibodies, Monoclonal; D012367:RNA, Viral; D003520:Cyclophosphamide